NovoCure (NVCR) FCF Margin (2014 - 2026)

NovoCure (NVCR) posted FCF Margin of 0.66% for Q2 2026, up 106.18% sequentially from 10.73% in Q1 2026, and up 1415.0% YoY from 0.04% in Q2 2025.

NovoCure (NVCR) FCF Margin (2014 - 2026) Analysis & Trends

NovoCure has reported FCF Margin for 13 years, with the latest figure at 0.66% in Q2 2026.

Quarterly FCF Margin rose 1415.0% year-over-year to 0.66% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.64% (up 912.0% YoY) and the FY2025 annual result came in at 11.55%, down 11.0% from the prior year.
FCF Margin advanced to 0.66% in Q2 2026 per NVCR's latest filing, from 10.73% in the prior quarter.
Over five years, FCF Margin peaked at 12.76% in Q3 2022 and troughed at 31.3% in Q1 2024.
A 5-year average of 9.88% and a median of 9.74% in 2024 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin sank 3363 bps in 2023, then soared 2067 bps in 2024.
Over 5 years, FCF Margin stood at 7.89% in 2022, then plunged by 102 bps to 15.98% in 2023, then jumped by 52 bps to 7.68% in 2024, then plunged by 71 bps to 13.13% in 2025, then soared by 105 bps to 0.66% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 0.66%, 10.73%, and 13.13% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	199.61 Bn	194.01 Bn	7.27 Bn	15.81%
2	Stryker	127.81 Bn	124.34 Bn	4.50 Bn	16.07%
3	Medtronic	119.04 Bn	109.82 Bn	6.41 Bn	21.26%
4	Boston Scientific	73.68 Bn	73.14 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.96 Bn	47.71 Bn	1.35 Bn	33.60%
6	Dexcom	34.36 Bn	32.41 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.83 Bn	31.72 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn	5.32%
9	Steris	23.06 Bn	22.58 Bn	684.20 Mn	18.73%
10	NovoCure	2.05 Bn	1.61 Bn	142.48 Mn	0.66%

Download Data